Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Cancer02:18

Cancer

49.9K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
49.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Vaccines01:30

Cancer Vaccines

522
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
522
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Oncology Research Information Exchange Network (ORIEN) - Building a real-world collaborative, patient-driven infrastructure for discovery research and precision oncology.

Research square·2026
Same author

Patient Out-of-Pocket Costs and Healthcare Utilization Related to Mastectomy vs Breast Conservation: A Claims-Based Study.

Journal of surgical oncology·2026
Same author

A novel case report of hepatic artery bypass following pancreaticoduodenectomy in the setting of median arcuate ligament-associated celiac artery stenosis.

International journal of surgery case reports·2026
Same author

ASO Visual Abstract: Adjuvant Radiotherapy After Pancreaticoduodenectomy for Margin-Negative, Node-Positive Pancreatic Ductal Adenocarcinoma: A Nationwide Analysis.

Annals of surgical oncology·2026
Same author

ASO Author Reflections: Does Nodal Disease Alone Warrant Adjuvant Radiotherapy after Pancreaticoduodenectomy?

Annals of surgical oncology·2026
Same author

Publisher Correction: Integrated Liquid Biopsy and Tumor Tissue Genomic Profiling of Appendiceal Cancer: cfDNA Burden, Mutation Landscapes, and Clinical Outcomes.

Annals of surgical oncology·2026
Same journal

Feasibility of uniportal thoracoscopic sublobar resection without chest tube drainage: a retrospective cohort study.

Frontiers in oncology·2026
Same journal

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China.

Frontiers in oncology·2026
Same journal

Caregiver satisfaction with early integrated palliative care in oncology: secondary outcomes from the PALLiON cluster-RCT.

Frontiers in oncology·2026
Same journal

Intracranial mesenchymal tumor with FET::CREB fusion: a rare case report.

Frontiers in oncology·2026
Same journal

The multifaceted roles of mitochondria and their therapeutic transformation: a new perspective on triple-negative breast cancer treatment.

Frontiers in oncology·2026
Same journal

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study.

Frontiers in oncology·2026
See all related articles

Related Experiment Video

Updated: Sep 20, 2025

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

4.6K

Bringing value to cancer research.

Casey J Allen1, Horn M Danea2, Fabrice Smieliauskas3

  • 1Division of Surgical Oncology, Institute of Surgery, Allegheny Health Network, Pittsburgh, PA, United States.

Frontiers in Oncology
|May 30, 2025
PubMed
Summary
This summary is machine-generated.

This study advocates for a broader definition of value in cancer clinical trials, including patient-reported outcomes and cost-effectiveness. A new framework and visual tool aim to improve shared decision-making and patient-centered cancer care.

Keywords:
clinical trialscostgoal-concordant carequalityshared decision-making

More Related Videos

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.0K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.9K

Related Experiment Videos

Last Updated: Sep 20, 2025

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

4.6K
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.0K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.9K

Area of Science:

  • Oncology
  • Health Economics
  • Clinical Trial Design

Background:

  • Current cancer clinical trials predominantly assess efficacy and safety.
  • Existing frameworks often overlook crucial patient-centered aspects like quality of life, financial toxicity, and time burden.
  • Cost-effectiveness is frequently not integrated into trial value assessments.

Purpose of the Study:

  • To propose a comprehensive framework for defining and measuring value in cancer clinical trials.
  • To advocate for the integration of patient-reported outcomes (PROs) and cost analyses alongside traditional endpoints.
  • To introduce a visual tool for enhanced value-based shared decision-making.

Main Methods:

  • Development of a novel framework integrating oncologic outcomes, PROs, and cost analyses.
  • Proposal of a multidimensional visual tool (e.g., radar chart) for value assessment.
  • Emphasis on a collaborative stakeholder approach to define value metrics.

Main Results:

  • The proposed framework offers a more holistic approach to evaluating cancer trial outcomes.
  • A visual tool can aid in presenting complex value data for shared decision-making.
  • Standardizing value assessment can lead to more equitable and effective cancer care.

Conclusions:

  • Incorporating a broader definition of value, including PROs and cost-effectiveness, is essential for patient-centered cancer care.
  • A collaborative, multidimensional approach to value assessment can improve clinical trial design and patient outcomes.
  • Standardization of value assessment in cancer research is a critical goal for enhancing care equity and effectiveness.